

Apixaban (Eliquis) Drug Level, Medical 303

Table of Content

Purpose
Description & Definitions
Criteria
Coding
Document History
References
Special Notes

Effective Date 4/2019

Next Review Date 6/2025

Coverage Policy Medical 303

Version 4

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details.

Purpose:

Keywords

This policy addresses the medical necessity of - Apixaban (Eliquis) Drug Level

Description & Definitions:

Apixaban Drug Level testing the level of a direct oral anticoagulant (DOAC) medication in the blood stream.

Criteria:

Apixaban (Eliquis) Drug Level is considered not medically necessary for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
80299	Quantitation of therapeutic drug, not elsewhere specified.

U.S. Food and Drug Administration (FDA) - approved only products only.

<u>Document History:</u>

Revised Dates:

Reviewed Dates:

2024: June – no changes references updated

Medical 303 Page 1 of 3

2023: June2022: June2021: August

2020: August

Effective Date:

April 2019

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Federal Register. Daily Journal of the United States Government. Retrieved 5.30.2024. https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=apixaban

U.S. Food and Drug Administration. Understanding the contribution of laboratory data linked to administrative claims: a case study looking at renal function and oral anticoagulant performance in patients with atrial fibrillation. 11.17.2023. Retrieved 5.30.2024. https://www.fda.gov/science-research/advancing-regulatory-science/understanding-contribution-laboratory-data-linked-administrative-claims-case-study-looking-renal

Hayes. A symplr company. Retrieved 5.30.2024.

https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Apixaban%2520(Eliquis)%2520Drug%2520Level%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%252all%2522,%2522sources%2522:%255B%2522*%2522*%2522*%255D,%2522sorts%2522:%255B%257B%2522field%2522:%255B%255D,%2522sources%2522;%2522direction%2522:%2522desc%2522%257D%255D,%2522filters%2522:%255B%255D%257D

MCG Informed Care Strategies. Retrieved 5.30.2024. https://careweb.careguidelines.com/ed27/index.html

Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 5.30.2024. https://www.cms.gov/search/cms?keys=80299

Commonwealth of Virginia. Department of Medical Assistance Services. Retrieved 5.30.2024 <a href="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals-provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals-provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort="https://vamedicaid.dmas.virginia.gov/manuals-provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort=1&gsc.q=80299&gsc.sort=1&gsc.q=80299&gsc.q=80299&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8029&gsc.q=8

Commonwealth of Virginia. Department of Medical Assistance Services. DMAS Fee Schedule. Retrieved 5.30.2024 https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT

National Comprehensive Cancer Network. Submission Request History. Apixaban Submitted by Bristol-Myers Squibb Company on 04/06/2020. Retrieved 5.30.2024. https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history

Carelon clinical guidelines and pathways. Retrieved 5.30.2024. https://guidelines.carelonmedicalbenefitsmanagement.com/no-search-results-found/

Avalon. Retrieved 5.30.2024. https://www.avalonhcs.com/policies-sentarahealth/

American College of Cardiology. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Jan 2024. Retrieved 5.30.2024. https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017?ga=2.105885259.976840480.1717093444-469703599.1711482484

Medical 303 Page 2 of 3

Towers, W., Nguyen, S. N., Ruegger, M. C., Salazar, E., & Donahue, K. R. (2022). Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury. The Annals of pharmacotherapy, 56(6), 656–663. Retrieved 5.30.2024. https://doi.org/10.1177/10600280211046087

Special Notes: *

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

Keywords:

SHP Apixaban Drug Level, SHP Medical 303, blood test, Eliquis

Medical 303 Page 3 of 3